In Specialty Pharma, First Horizon's Low Cost Sales Model
In 2003, after a string of bad luck that had sent its stock down 81%, First Horizon overhauled its management team and began to implement a new low-cost sales strategy. It appears to be working. First quarter 2004 income was $8.2 million, compared to a loss of almost $14 million a year ago. Prescriptions of its key product, calcium channel blocker nisoldipine (Sular), were up 10% in the quarter, and this was evidently enough to convince pharmaceutical company SkyePharma PLC to grant the specialty pharma US marketing rights to an unnamed cardiovascular product.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.